IL6 and metabolic dysfunction-associated steatotic liver disease: Studies have shown that serum IL-6 levels in NAFLD patients are significantly higher than those in healthy controls(P =0.0179), and serum IL-6 levels in patients with liver fibrosis (S1, S2-3) are higher than those in non-fibrotic patients(P< 0.05) (57).